Progression-free survival and overall survival in patients with advanced her2-positive breast cancer treated with trastuzumab emtansine (T-dm1) after previous treatment with pertuzumab

Michel LL, Hartkopf AD, Fasching P, Kolberg HC, Hadji P, Tesch H, Häberle L, Ettl J, Lüftner D, Wallwiener M, Müller V, Beckmann M, Belleville E, Volz B, Hübner H, Wimberger P, Hielscher C, Mundhenke C, Kurbacher C, Wuerstlein R, Untch M, Overkamp F, Huober J, Janni W, Taran FA, Lux MP, Wallwiener D, Brucker SY, Schneeweiss A, Fehm TN (2020)

Publication Type: Journal article

Publication year: 2020

Journal

Book Volume: 12

Pages Range: 1-15

Article Number: 3021

Journal Issue: 10

DOI: 10.3390/cancers12103021

Abstract

The approval of trastuzumab emtansine (T-DM1) was conducted without pertuzumab as previous therapy. Efficacy data on T-DM1 following pertuzumab treatment are therefore limited. This study explores this issue in a real-world setting. Within the prospective PRAEGNANT (Prospective Academic Translational Research Network for the Optimization of the Oncological Health Care Quality in the Advanced Setting) metastatic breast cancer registry (NCT02338167), patients in all therapy lines receiving any kind of treatment were eligible for inclusion. This report describes patient characteristics and progression-free survival (PFS) in human epidermal growth factor receptor 2 (HER2)-positive patients receiving T-DM1 after pertuzumab treatment. Seventy-six patients were identified, 39 of whom received T-DM1 as second-line therapy, 25 as third-line, and 12 as fourth-line therapy or higher. Pertuzumab was mostly administered as a first-line treatment (n = 61; 80.3%). The median PFS in all patients was 3.5 months (95% CI: 2.8–7.8); in second-line treatment, 7.7 months (95% CI: 2.8–11.0); in third-line, 3.4 months (95% CI: 2.3–not reached (NR)); and in fourth-line therapy or higher, 2.7 months (95% CI: 1.2–NR). T-DM1 was mainly administered second-line after pertuzumab, but also in more heavily pretreated patients. The PFS in higher therapy lines appears to be shorter than in second-line.

Authors with CRIS profile

Involved external institutions

Universitätsklinikum Heidelberg Germany (DE) Universitätsklinikum Hamburg-Eppendorf (UKE) Germany (DE) Marienhospital Bottrop Germany (DE) Charité - Universitätsmedizin Berlin Germany (DE) Agaplesion Markus Krankenhaus Germany (DE) Klinikum rechts der Isar Germany (DE) Eberhard Karls Universität Tübingen Germany (DE) Hochschule Ansbach Germany (DE) HELIOS Kliniken Germany (DE) ClinSol GmbH & Co.KG Germany (DE) Universitätsklinikum Ulm Germany (DE) Universitätsklinikum Carl Gustav Carus Dresden Germany (DE) Kooperatives Brustzentrum Paderborn Germany (DE) Gynäkologie Kompetenzzentrum Stralsund: gSUND Germany (DE) Medizinisches Zentrum Bonn Friedensplatz Germany (DE) Klinikum der Universität München Germany (DE) Universitätsklinikum Düsseldorf Germany (DE) OncoConsult Germany (DE) Universitätsspital Zürich (USZ) Switzerland (CH) Klinikum Bayreuth Germany (DE)

How to cite

APA:

Michel, L.L., Hartkopf, A.D., Fasching, P., Kolberg, H.C., Hadji, P., Tesch, H.,... Fehm, T.N. (2020). Progression-free survival and overall survival in patients with advanced her2-positive breast cancer treated with trastuzumab emtansine (T-dm1) after previous treatment with pertuzumab. Cancers, 12(10), 1-15. https://doi.org/10.3390/cancers12103021

MLA:

Michel, Laura L., et al. "Progression-free survival and overall survival in patients with advanced her2-positive breast cancer treated with trastuzumab emtansine (T-dm1) after previous treatment with pertuzumab." Cancers 12.10 (2020): 1-15.

BibTeX: Download